VEGF及MVD在卵巢上皮性肿瘤中的表达

Expression of VEGF and MVD in Epithelial Ovarian Tumors

目的:探讨VEGF表达及MVD在卵巢浆液性上皮性肿瘤进展中的作用。方法:采用SP免疫组织化学染色方法检测19例卵巢浆液性囊腺癌,15例交界性浆液性囊腺瘤和13例浆液性囊腺瘤中VEGF的表达情况,及MVD计数。结果:浆液性囊腺癌中VEGF(29.50±7.54)及MVD(25.16±8.44)显著高于交界性浆液性囊腺瘤(11.64±2.07,8.54±3.68)和浆液性囊腺瘤(1.55±1.23,1.88±0.85),均P=0.000,交界性浆液性囊腺瘤中VEGF、MVD显著高于浆液性囊腺瘤(P=0.006,P=0.000);VEGF、MVD在Ⅲ级卵巢浆液性囊腺癌中的表达(34.59±2.13,30.99±9.59)显著高于Ⅰ～Ⅱ级(26.53±7.04,21.76±6.60),P=0.020和P=0.023;8年生存患者癌组织中VEGF的表达(26.93±7.71)显著低于死亡患者(33.90±5.07),P=0.049,MVD计数未显示显著性差异,P=0.124;相关分析显示VEGF的表达与MVD呈显著正相关(P=0.000)。结论:VEGF及MVD在卵巢浆液性囊腺癌和交界性浆液性囊腺瘤中呈高表达,表明VEGF、MVD与卵巢浆液性上皮性肿瘤的进展有关,随着癌组织学分级的增高,VEGF、MVD呈现高表达,但与癌的临床分期无关,表明VEGF、MVD可能成为一个有用的评估卵巢浆液性上皮性肿瘤的辅助指标。

Objective: To investigate the expression of vascular endothelial growth factor (VEGF) and microvascular density (MVD) in serous ovarian tumors and their role in the progression of the tumor. Methods: Measuring the expression of VEGF and MVD by routine s-p immunohistochemistry in 19 serous ovarian cystoadenocarcinomas, 15 borderline serous ovarian cystoadenomas and 13 serous ovarian cystoadenomas. Results: The expression of VEGF and MVD in serous ovarian cystoadenocarcinomas (29.50±7.54 and 25.16±8.44) are significantly higher than those in borderline serous ovarian cystoadenomas (11.64±2.07,8.54±3.68) and serous ovarian cystoadenomas (1.55±1.23,1.88±0.85), P=0.000 for both; The expression of VEGF and MVD in borderline serous ovarian cystoadenomas are significantly higher than those in serous ovarian cystoadenomas, P=0.006 and P=0.000 respectively; The expression of VEGF and MVD in serous ovarian cystoadenocarcinomas grade Ⅲ (34.59±2.13 and 30.99±9.59) are significantly higher than those in carcinomas gradeⅠ～Ⅱ (26.53±7.04 and 21.76±6.60), P=0.020 and P=0.023 respectively; 8-year follow-up results showed that the expression of VEGF in the carcinoma tissue of living cases is significantly lower than that of the died cases, MVD did not show such significance; Correlation analysis showed that there was a positive correlation between the expression of VEGF and MVD (P=0.000). Conclusions: Our findings in this study indicate that the higher expression of VEGF and MVD in serous ovarian cystoadenocarcinomas and borderline serous ovarian cystoadenomas may play a role in the progression of serous ovarian tumors. VEGF and MVD may be a prospective auxiliary marks of evaluation of the prognosis due to their higher expressions in higher grade, although no relationship was found between the stage of carcinoma and their expression.